(Q36194937)

12 August 2017

1 reference

title

Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? (English)

1 reference

12 August 2017

main subject

osteogenesis imperfecta

0 references

author name string

Frank Rauch

series ordinal

1

1 reference

12 August 2017

Francis H Glorieux

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

37

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

295-302

1 reference

12 August 2017

cites work

Osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Type V osteogenesis imperfecta: a new form of brittle bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Osteogenesis imperfecta in childhood: treatment strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Intravenous neridronate in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Radiographic features of bisphosphonate therapy in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Osteogenesis imperfecta and intravenous pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

Intravenous bisphosphonate therapy in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510007386

10.1080/07853890510007386

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference